Maravai Lifesciences Holdings, INC Form 4 insider transactions

Bernd Brust, Chief Executive Officer and a Director of Maravai Lifesciences Holdings, Inc., reported a transaction in 29,250 shares of common stock on August 10, 2026.

Rajesh Asarpota, Chief Financial Officer of Maravai Lifesciences Holdings, Inc., reported a transaction in 5,465 shares of common stock on July 30, 2026.

Bernd Brust, CEO of Maravai Lifesciences Holdings, Inc., reported transactions involving Class A Common Stock, including shares withheld for tax obligations.

Rajesh Asarpota, Chief Financial Officer of Maravai Lifesciences Holdings, Inc., reported a transaction involving the withholding of shares to cover tax obligations.

Maravai LifeSciences CEO Bernd Brust disposed of 351,001 shares of Class A Common Stock to satisfy tax withholding obligations.

General Counsel Kurt Oreshack sold 50,000 shares of Maravai LifeSciences Holdings, Inc. under a pre-established 10b5-1 trading plan.

Maravai LifeSciences Director Gregory T. Lucier transferred 46,293 shares of Class A Common Stock to a family partnership.

Director Gregory T. Lucier filed an amendment to correct the reported purchase price of restricted stock units granted on May 26, 2026.

Maravai LifeSciences director Luke Marker was granted 46,293 restricted stock units as part of the company's 2020 Omnibus Incentive Plan.

Director Susannah Gray was granted 46,293 restricted stock units in Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences director Constantine Mihas was granted 46,293 restricted stock units as part of the company's 2020 Omnibus Incentive Plan.

Director R. Andrew Eckert was granted 46,293 restricted stock units in Maravai LifeSciences Holdings, Inc.

Director Gregory T. Lucier acquired 46,293 shares of Maravai LifeSciences Holdings, Inc. through a restricted stock unit grant.

Director Sean Cunningham was awarded 46,293 restricted stock units of Maravai LifeSciences Holdings, Inc. on May 26, 2026.

Director John DeFord was granted 46,293 restricted stock units in Maravai LifeSciences Holdings, Inc.

Executive Vice President Christine Dolan acquired 5,006 shares of Maravai LifeSciences Class A Common Stock via the company's Employee Stock Purchase Plan.

General Counsel Kurt Oreshack acquired 776 shares of Maravai LifeSciences Class A Common Stock via the employee purchase plan.

Christine Dolan, EVP & General Manager of Cygnus Technologies, disposed of 28,661 Maravai Lifesciences shares to cover tax obligations from restricted stock unit vesting.

Maravai LifeSciences General Counsel Kurt Oreshack disposed of 39,976 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Maravai LifeSciences Holdings, Inc. Executive Vice President Christine Dolan disposed of 28,934 shares of Class A Common Stock to cover tax obligations related to restricted stock unit vesting.

Maravai LifeSciences General Counsel, Kurt Oreshack, disposed of 31,902 Class A Common Stock shares to cover tax withholding obligations related to vested restricted stock units.

Maravai LifeSciences director Gregory T. Lucier increased his direct ownership in the company by purchasing 100,000 shares of Class A Common Stock through a pre-arranged trading plan.

Christine Dolan, an officer at Maravai LifeSciences Holdings, Inc., plans to acquire 4,300 shares of Class A Common Stock through an employee stock purchase plan.

Maravai LifeSciences CEO Bernd Brust acquired 216,212 shares of Class A Common Stock through a trust, indicating strong insider confidence.

Maravai LifeSciences CEO Bernd Brust acquired 250,559 shares of Class A Common Stock through his management trust in two transactions on November 11 and 12, 2025.

Maravai LifeSciences Chief Administrative Officer Peter Leddy reported the disposition of 5,154 shares of Class A Common Stock at $2.59 per share to cover tax withholding obligations related to restricted stock unit vesting.

Maravai LifeSciences Holdings, Inc. Director Gregory T. Lucier reported gifting 89,139 shares of Class A Common Stock to a family partnership, altering his direct and indirect beneficial ownership.

Maravai LifeSciences Holdings, Inc. Chief Financial Officer Rajesh Asarpota has been granted 500,000 restricted stock units, 333,333 stock options, and 750,000 performance stock units, all vesting over three years subject to continued employment and performance conditions.

Maravai LifeSciences Holdings, Inc. Director Benjamin Daverman acquired 89,139 shares of Class A Common Stock through a restricted stock unit grant on June 16, 2025, increasing his indirect beneficial ownership.

Maravai LifeSciences Holdings, Inc. Director Susannah Gray was granted 89,139 restricted stock units (RSUs) valued at $2.16 per unit, aligning her interests with shareholders.